The Gastric Cancer Therapy Market size was valued at US$ 3.52 Bn in 2022 and the total revenue is expected to grow at 4.3% through 2022 to 2029, reaching nearly US$ 4.72 Bn.Gastric Cancer Therapy Market Overview:
Gastric Cancer Therapy is caused by uncontrolled abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as Gastric Cancer Therapy or stomach cancer. Diet and stomach disorders are both risk factors for Gastric Cancer Therapy. Stomach pain, poor appetite, weight loss, indigestions, nausea, vomiting with or without blood are some of the symptoms of Gastric Cancer Therapy.To know about the Research Methodology :- Request Free Sample Report
Gastric Cancer Therapy Market Dynamics:
Over the forecast period, the worldwide Gastric Cancer Therapy treatment market is expected to increase significantly. Gastric Cancer Therapy is a type of cancer that starts when cancer cells develop in the stomach's inner lining. Gastric Cancer Therapy normally takes a long time to develop. However, if the stomach tumor grows, more dangerous symptoms such as stomach discomfort, vomiting, yellowing eyes or skin, blood in the stool, constipation, stomach bloating, weight loss, and so on may develop. Gastric Cancer Therapy treatment is mostly determined by cancer's stage. Surgery-targeted medications, chemotherapy, and other treatments are among the options available. Treatment advancements, an increase in the number of cancer treatment facilities, increased research and development activities, and combination medicines are all aspects that are propelling the global market forward. According to GLOBOCAN estimations, the greatest rate of stomach cancer in 2018 was in South Korea, followed by Mongolia. In 2018, the stomach cancer rate in South Korea was 57.8% for males and 23.5 % were female. 5-FU, Capecitabine, Carboplatin, Cisplatin, Docetaxel, Epirubicin, Irinotecan, Oxaliplatin, and Paclitaxel are some of the chemotherapy medications used to treat stomach cancer. Hence, the increasing frequency of cancer diseases is likely to boost the treatment market. Furthermore, the rising prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumors, carcinoid tumors, and other cancers is propelling the global market forward. On the other side, there are certain constraints that are limiting the market's growth, such as high therapy costs of overall treatment and a lack of adequate financial support from health insurance policies.Gastric Cancer Therapy Market Segment Analysis:
The Chemotherapy segment is dominating the Therapy Type segment of the Gastric Cancer Therapy Market: In the Gastric Cancer Therapy Market, the Chemotherapy Segment is Expected to Hold a Major Market Share. Chemotherapy is the most prevalent type of treatment for cancer cells that are used to stop or slow their proliferation of unwanted cells. Chemotherapy works by eliminating, destroying, or damaging cancer cells in a specific region, whereas surgery and radiation therapy function across the body. Chemotherapy can therefore kill and harm cancer cells that have spread to other parts of the body, distant from the original tumor. Even though chemotherapy has several side effects, it is still the treatment of choice for most doctors around the world. When compared to immunotherapies, it is also less expensive, and it can be taken orally or intravenously. Hence these factors are likely to support the growth of the market in the coming future.The Hospital segment is considered to supplement the growth of the Gastric Cancer Therapy Market. In 2022, the hospital's segment dominated the market. The hospitals market is projected to be driven by regional government initiatives to enhance health care infrastructure. Further, the availability of technicians and radiologists in hospitals and patient convenience is a major factor dominating the growth of the hospital segment. Also, hospitals are adopting various technologies to offer precise and targeted organ therapies to improve patient conditions. Moreover, cancer therapies are extremely carried out under physician’s supervision hence, due to this factor hospital segment is projected to grab more market attention in the forecast time frame.
Gastric Cancer Therapy Market Regional Insights:
North America is likely to boost the growth of the Gastric Cancer Therapy Market. Throughout the projected period, North America is expected to lead the global market. The US. had the greatest market share in 2019 in North America The increased prevalence of gastric cancer, as well as the availability of improved technologies in cancer research and treatment institutes, are to blame. According to predictions from the American Cancer Society, approximately 27,600 cases of stomach cancer will be detected in 2021. (16,970 in men and 10,621 in women). Furthermore, around 11,010 people will die from gastric cancer (6,650 men and 4,360 women). Besides, the country is very much in terms of modern cancer treatment technologies, and medical device businesses are vying for market share against established competitors in the US. and Canada. Such factors contribute to the market's expansion in North America. The objective of the report is to present a comprehensive analysis of the Gastric Cancer Therapy Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Gastric Cancer Therapy Market dynamics, structure by analyzing the market segments and project the Gastric Cancer Therapy Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Gastric Cancer Therapy Market make the report investor’s guide.Gastric Cancer Therapy Market Scope: Inquire before buying
Global Gastric Cancer Therapy Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 3.52 Bn. Forecast Period 2023 to 2029 CAGR: 4.3% Market Size in 2029: US $ 4.72 Bn. Segments Covered: by Product Chemotherapy Targeted Therapy Immunotherapy Radiation Therapy Surgery by Type Ambulatory Surgery Centers Hospitals and Specialty Clinics Other End users Gastric Cancer Therapy Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Gastric Cancer Therapy Market Key Player
1. Novartis AG 2. Glaxo SmithKline Plc 3. Roche Holding Limited 4. AptarGroup Incorporated 5. Squibb Company 6. Boston Scientific Corporation 7. Pfizer. 8. Agilent Technologies, Inc. 9. Illumina, Inc. 10.Thermo Fisher Scientific, Inc. 11.General Electric Company 12.BD 13.Abbott 14.QIAGEN 15.Siemens Healthcare GmbH 16.F. Hoffmann-La Roche Ltd. 17.Koninklijke Philips N.V. 18.Eli Lilly and Company 19.F. Hoffmann-La Roche Ltd. 20.Merck KGaA 21.Otsuka Holdings Co. Ltd FAQs: 1. What is the Gastric Cancer Therapy market value in 2022? Ans: Gastric Cancer Therapy market value in 2022 was estimated as 3.52 Billion USD. 2. What is the Gastric Cancer Therapy market growth? Ans: The Gastric Cancer Therapy market is anticipated to grow with a CAGR of 4.3% in the forecast period and is likely to reach USD 4.72 Billion by the end of 2029. 3. Which Therapy segment is expected to dominate the Gastric Cancer Therapy market during the forecast period? Ans: The Chemotherapy segment is projected to lead the market growth owing to low cost and precise treatment option as compare to other. Also chemo therapy is one of the most preferred among all. 4. Who are the key players in the Gastric Cancer Therapy market? Ans: Some key players operating in the Gastric Cancer Therapy market include Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck KGaA, Novartis International AG, and Otsuka Holdings Co. Ltd. 5. What is the key driving factor for the growth of the Gastric Cancer Therapy market? Ans: Key factors that are driving the Gastric Cancer Therapy market growth include Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma; rise in alcohol consumption, surge in smoking, and increase in the geriatric population are anticipated to boost the growth of the global Gastric Cancer Therapy testing market
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Gastric Cancer Therapy Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Gastric Cancer Therapy Market 3.4. Geographical Snapshot of the Gastric Cancer Therapy Market, By Manufacturer share 4. Gastric Cancer Therapy Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Gastric Cancer Therapy Market 5. Supply Side and Demand Side Indicators 6. Gastric Cancer Therapy Market Analysis and Forecast, 2022-2029 6.1. Gastric Cancer Therapy Market Size & Y-o-Y Growth Analysis. 7. Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 7.1.1. Chemotherapy 7.1.2. Targeted Therapy 7.1.3. Immunotherapy 7.1.4. Radiation Therapy 7.1.5. Surgery 7.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 7.2.1. Ambulatory Surgery Centers 7.2.2. Hospitals and Specialty Clinics 7.2.3. Other End users 8. Gastric Cancer Therapy Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 9.1.1. Chemotherapy 9.1.2. Targeted Therapy 9.1.3. Immunotherapy 9.1.4. Radiation Therapy 9.1.5. Surgery 9.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 9.2.1. Ambulatory Surgery Centers 9.2.2. Hospitals and Specialty Clinics 9.2.3. Other End users 10. North America Gastric Cancer Therapy Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 12. Canada Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 13. Mexico Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 14. Europe Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 15. Europe Gastric Cancer Therapy Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 17. France Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 18. Germany Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 19. Italy Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 20. Spain Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 21. Sweden Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 22. CIS Countries Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 23. Rest of Europe Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 24. Asia Pacific Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 25. Asia Pacific Gastric Cancer Therapy Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 27. India Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 28. Japan Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 29. South Korea Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 30. Australia Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 31. ASEAN Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 32. Rest of Asia Pacific Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 33. Middle East Africa Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 34. Middle East Africa Gastric Cancer Therapy Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 36. GCC Countries Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 38. Nigeria Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 39. Rest of ME&A Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 40. South America Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 41. South America Gastric Cancer Therapy Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 43. Argentina Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 44. Rest of South America Gastric Cancer Therapy Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 44.2. Market Size (Value) Estimates & Forecast By End-User, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Gastric Cancer Therapy Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Pfizer (Hospira) 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. Amgen Incorporated 45.3.3. AstraZeneca plc 45.3.4. Abbott Laboratories 45.3.5. Baxter International Incorporated 45.3.6. Becton 45.3.7. Dickinson, and Company 45.3.8. Bristol-Myers Squibb Company 45.3.9. AptarGroup Incorporated 45.3.10. Pfizer Incorporated 45.3.11. GlaxoSmithKline Plc 45.3.12. Roche Holding Limited 45.3.13. AptarGroup Incorporated 45.3.14. Squibb Company 45.3.15. Boston Scientific Corporation 45.3.16. GlaxoSmithKline plc 45.3.17. Roche Holding Limited 45.3.18. Novartis AG 46. Primary Key Insights